Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 69, No 1 (2018)
Original paper
Submitted: 2017-07-01
Accepted: 2017-09-19
Published online: 2017-12-21
View PDF Download PDF file
Get Citation

A preliminary study on the expression and clinical value of platelet-derived growth factor BB, hypoxia inducible factor-1α and C-C motif chemokine receptor-2 in peripheral blood during the pathogenesis of Graves’ disease

Ying Liu1, Jinglan Tang1, Qiaohong Hu1, Kefeng Lu1, Chunjie Hou1
DOI: 10.5603/EP.a2018.0004
·
Pubmed: 29319128
·
Endokrynol Pol 2018;69(1):9-15.
Affiliations
  1. Master of Medicine. Department of ultrasonography, Zhejiang Provincial People’s Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, P R China, China

open access

Vol 69, No 1 (2018)
Original Paper
Submitted: 2017-07-01
Accepted: 2017-09-19
Published online: 2017-12-21

Abstract

Introduction: Platelet-derived growth factor BB (PDGF-BB) plays an important role in the development of GD (Graves’ disease). However, it is still unknown whether PDGF-BB is expressed in peripheral blood and whether the expression of PDGF-BB contributes to GD. We aim to study the expression of PDGF-BB, hypoxia inducible factor (HIF)-1α and C-C motif chemokine receptor (CCR)-2 in peripheral blood of patients with GD and explore its effect and potential mechanism in pathogenesis. Material and methods: 41 patients with GD (GD group) and forty-five healthy people (control group) were chosen. The concentration of PDGF-BB and HIF-1α in peripheral blood specimens were detected and compared between the two groups. The expression of CCR2 in macrophages in the peripheral blood specimens were examined using FCM (Flow Cytometry). Results: Both PDGF-BB and HIF-1α were expressed in human peripheral blood from the two groups. Compared with specimens from healthy people, there were statistically increased concentrations of PDGF-BB and HIF-1α in the GD group (P < 0.05). The proportion of CCR2-positive macrophages in peripheral blood in the GD group was significantly higher than that in the control group (P < 0.05). Conclusions: CCR2-positive macrophages may induce the expression of PDGF-BB through HIF-1α signal, and the high expression of PDGF-BB may be involved in the pathogenesis of GD.

Abstract

Introduction: Platelet-derived growth factor BB (PDGF-BB) plays an important role in the development of GD (Graves’ disease). However, it is still unknown whether PDGF-BB is expressed in peripheral blood and whether the expression of PDGF-BB contributes to GD. We aim to study the expression of PDGF-BB, hypoxia inducible factor (HIF)-1α and C-C motif chemokine receptor (CCR)-2 in peripheral blood of patients with GD and explore its effect and potential mechanism in pathogenesis. Material and methods: 41 patients with GD (GD group) and forty-five healthy people (control group) were chosen. The concentration of PDGF-BB and HIF-1α in peripheral blood specimens were detected and compared between the two groups. The expression of CCR2 in macrophages in the peripheral blood specimens were examined using FCM (Flow Cytometry). Results: Both PDGF-BB and HIF-1α were expressed in human peripheral blood from the two groups. Compared with specimens from healthy people, there were statistically increased concentrations of PDGF-BB and HIF-1α in the GD group (P < 0.05). The proportion of CCR2-positive macrophages in peripheral blood in the GD group was significantly higher than that in the control group (P < 0.05). Conclusions: CCR2-positive macrophages may induce the expression of PDGF-BB through HIF-1α signal, and the high expression of PDGF-BB may be involved in the pathogenesis of GD.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

PDGF-BB, Graves’ disease, HIF-1α, macrophages, immunology

About this article
Title

A preliminary study on the expression and clinical value of platelet-derived growth factor BB, hypoxia inducible factor-1α and C-C motif chemokine receptor-2 in peripheral blood during the pathogenesis of Graves’ disease

Journal

Endokrynologia Polska

Issue

Vol 69, No 1 (2018)

Article type

Original paper

Pages

9-15

Published online

2017-12-21

Page views

1530

Article views/downloads

1200

DOI

10.5603/EP.a2018.0004

Pubmed

29319128

Bibliographic record

Endokrynol Pol 2018;69(1):9-15.

Keywords

PDGF-BB
Graves’ disease
HIF-1α
macrophages
immunology

Authors

Ying Liu
Jinglan Tang
Qiaohong Hu
Kefeng Lu
Chunjie Hou

References (19)
  1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22(10): 1276–1312.
    CrossRefPubMed
  2. Chen XS, Sun D, Yao X. Research Progress on PDGF/PDGFR in Cancer and Related Targeted Therapy. Chinese Journal of Clinical Oncology. 2012; 39: 1134–1137.
  3. Li Q, Ma LK. Role and Possible Mechanism of PDGF Signaling Pathways During Process of Myocardial Fibrosis Induced by Aldosterone. Advances in Cardiovascular Diseases. 2012; 33: 85–88.
  4. Liu HJ, Gao XZ, Jin Y, et al. Role of PDGFR-β signal pathway in morphine tolerance. Journal of Medical Postgraduates. 2015; 28: 149–152.
  5. Cheng P, Gao ZQ, Liu YH, et al. Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett. 2009; 451(1): 52–56.
    CrossRefPubMed
  6. Cheng J, Ye H, Liu Z, et al. Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J Cell Biochem. 2013; 114(7): 1510–1518.
    CrossRefPubMed
  7. Wang BL, Wang XR. Regulation of the hypoxia inducible factor-1α by the inflammatory mediators[J]. Inter J Pathol Clin Med. 2008; 90: 1673–1688.
  8. Yoshimura T, Robinson EA, Tanaka S, et al. Purification and am ino acid analysis of two human glioma-derived monocyte chemoattractants[ J] . J ExpMed. 1989; 169: 1449–1459.
  9. Lee EY, Chung CH, Khoury CC, et al. The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol. 2009; 297(1): F85–F94.
    CrossRefPubMed
  10. Chen BY, Guan CN. The research progress of relationship between MCP-1 and HIF-1 and tumor angiogenesis. JMed Res. 2010; 39: 27–30.
  11. Chen SJ, Xu XJ, Huo X. Research Development about Relationship of PDGFs and its Receptor with Related Diseases. Medical Recapitulate. 2008; 14: 1441–1444.
  12. Qi L, Du J, Zhang Z, et al. Low differentiated microvascular density and low expression of platelet-derived growth factor-BB (PDGF-BB) predict distant metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2013; 112(4): E415–E423.
    CrossRefPubMed
  13. van Steensel L, Hooijkaas H, Paridaens D, et al. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients. J Clin Endocrinol Metab. 2012; 97(6): E944–E953.
    CrossRefPubMed
  14. Compile Group of Endocrinology branch of Chinese medical association. Chinese guidelines of diagnosis and treatment of thyroid diseases - Hyperthyroidism. Chinese Journal of Internal Medicine. 2007; 46: 876–882.
  15. Tang YG. Analysis of the clinical effect of methimazole combined with levothyroxine for treating hyperthyroid exophthalmos. Heilongjiang Medical Journal. 2016; 29: 279–280.
  16. Fang WZ, Luo ZW. Progress in Treatment of Graves Ophthalmopathy. Medical Recapitulate. 2014; 20: 3534–3536.
  17. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves' disease. Autoimmun Rev. 2014; 13(4-5): 398–402.
    CrossRefPubMed
  18. Scholz CC, Taylor CT. Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol. 2013; 13(4): 646–653.
    CrossRefPubMed
  19. Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627): 112–117.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl